91 results on '"Vetta G"'
Search Results
2. Pulmonary vein isolation with the radiofrequency balloon catheter: long-term results and predictors of ablation success
- Author
-
Del Monte, A, primary, Almorad, A, additional, Della Rocca, D G, additional, Pannone, L, additional, Vetta, G, additional, Cespon Fernandez, M, additional, Doundoulakis, I, additional, Marcon, L, additional, Monaco, C, additional, Bala, G, additional, Stroker, E, additional, Sieira, J, additional, Sarkozy, A, additional, Chierchia, G B, additional, and De Asmundis, C, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Preventing vagal response during pulmonary vein isolation with pulsed field ablation: impact of the order of the targeted pulmonary veins
- Author
-
Del Monte, A, primary, Della Rocca, D G, additional, Pannone, L, additional, Vetta, G, additional, Cespon Fernandez, M, additional, Doundoulakis, I, additional, Marcon, L, additional, Monaco, C, additional, Bala, G, additional, Stroker, E, additional, Sieira, J, additional, Almorad, A, additional, Sarkozy, A, additional, Chierchia, G B, additional, and De Asmundis, C, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Multielectrode catheter-based pulsed electric field versus cryoballoon for atrial fibrillation ablation: a systematic review and meta-analysis
- Author
-
Vetta, G, primary, Della Rocca, D G, additional, Parlavecchio, A, additional, Magnocavallo, M, additional, Pannone, L, additional, Sorgente, A, additional, Sieira, J, additional, Almorad, A, additional, Bala, G, additional, Stroker, E, additional, Rossi, P, additional, Boveda, S, additional, Sarkozy, A, additional, De Asmundis, C, additional, and Chierchia, G B, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Comparison of pulsed field and radiofrequency ablation for non-paroxysmal atrial fibrillation: a propensity score-matched analysis
- Author
-
Sousonis, V, primary, Boveda, S, additional, Della Rocca, D G, additional, Albenque, J P, additional, Benadel, M, additional, Doundoulakis, I, additional, Zeriouh, S, additional, Vetta, G, additional, Mene, R, additional, Betancur, A, additional, Pannone, L, additional, Sarkozy, A, additional, Chierchia, G B, additional, De Asmundis, C, additional, and Combes, S, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Multielectrode catheter-based pulsed field ablation of persistent and long-standing persistent atrial fibrillation
- Author
-
Della Rocca, D, primary, Sorgente, A, additional, Pannone, L, additional, Stroker, E, additional, Vetta, G, additional, Doundoulakis, I, additional, Del Monte, A, additional, Mouram, S, additional, Mene, R, additional, Betancur, A, additional, Boveda, S, additional, Natale, A, additional, Sarkozy, A, additional, De Asmundis, C, additional, and Chierchia, G B, additional
- Published
- 2024
- Full Text
- View/download PDF
7. First multicenter experience of pulmonary vein and posterior wall isolation via a novel focal 9mm lattice tip catheter in a real-world scenario
- Author
-
Vetta, G, primary, Della Rocca, D G, additional, Pannone, L, additional, Sorgente, A, additional, Cespon-Fernandez, M, additional, Del Monte, A, additional, Mene, R, additional, Almorad, A, additional, Sieira, J, additional, Bala, G, additional, Stroker, E, additional, Boveda, S, additional, Sarkozy, A, additional, De Asmundis, C, additional, and Chierchia, G B, additional
- Published
- 2024
- Full Text
- View/download PDF
8. Preliminary real-world experience on mitral isthmus ablation with a novel catheter that toggles between radiofrequency and pulsed field ablation
- Author
-
Mene', R, primary, Albenque, J P, additional, Della Rocca, D, additional, Combes, S, additional, Sousonis, V, additional, Vetta, G, additional, Saitta, F, additional, Zeriouh, S, additional, Pannone, L, additional, Betancur, A, additional, Sarkozy, A, additional, Chierchia, G B, additional, Benadel, M, additional, De Asmundis, C, additional, and Boveda, S, additional
- Published
- 2024
- Full Text
- View/download PDF
9. First experience of focal pulsed field ablation for premature ventricular contractions
- Author
-
Cespon Fernandez, M, primary, Della Rocca, D G, additional, Almorad, A, additional, Vetta, G, additional, Del Monte, A, additional, Pannone, L, additional, Mouram, S, additional, Sorgente, A, additional, Sieira, J, additional, Stroker, E, additional, Bala, G, additional, Overeinder, I, additional, Chierchia, G B, additional, De Asmundis, C, additional, and Sakorzy, A, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Left atrial appendage clipping during hybrid atrial fibrillation ablation: a very long-term, single-center experience
- Author
-
Mouram, S, primary, Della Rocca, D G, additional, Doundoulakis, I, additional, Pannone, L, additional, Vetta, G P, additional, Stroker, E, additional, Almorad, A, additional, Sieira, J, additional, Sarkozy, A, additional, Chierchia, G B, additional, La Meir, M, additional, and De Asmundis, C, additional
- Published
- 2024
- Full Text
- View/download PDF
11. Procedural characteristics, details on epicardial mapping-based lesion transmurality, and long-term success of posterior wall isolation with a pentaspline pulsed field ablation device
- Author
-
Della Rocca, D, primary, Cespon-Fernandez, M, additional, Glowniak, A, additional, Sousonis, V, additional, Vetta, G, additional, Magnocavallo, M, additional, Pannone, L, additional, Sorgente, A, additional, Mene, R, additional, Del Monte, A, additional, Sarkozy, A, additional, Boveda, S, additional, Natale, A, additional, De Asmundis, C, additional, and Chierchia, G B, additional
- Published
- 2024
- Full Text
- View/download PDF
12. Acute and long-term lesion durability and reconnection patterns following hybrid atrial fibrillation ablation
- Author
-
Mouram, S, primary, Della Rocca, D G, additional, Doundoulakis, I, additional, Pannone, L, additional, Vetta, G P, additional, Stroker, E, additional, Almorad, A, additional, Sieira, J, additional, Sarkozy, A, additional, Chierchia, G B, additional, La Meir, M, additional, and De Asmundis, C, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Prophylactic administration of glycopyrrolate prevents vasovagal responses induced by pulsed field ablation in patients with atrial fibrillation
- Author
-
Vetta, G, primary, Della Rocca, D G, additional, Cespon-Fernandez, M, additional, Del Monte, A, additional, Magnocavallo, M, additional, Mene, R, additional, Pannone, L, additional, Sorgente, A, additional, Sieira, J, additional, Stroker, E, additional, Rossi, P, additional, Boveda, S, additional, Sarkozy, A, additional, De Asmundis, C, additional, and Chierchia, G B, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Axillary vein puncture versus cephalic vein cutdown for cardiac implantable electronic device implantation: a meta-analysis
- Author
-
Vetta, G, primary, Magnocavallo, M, additional, Parlavecchio, A, additional, Caminiti, R, additional, Polselli, M, additional, Sorgente, A, additional, Crea, P, additional, Pannone, L, additional, Lo Savio, A, additional, Pistelli, L, additional, Chierchia, G B, additional, Rossi, P, additional, Natale, A, additional, De Asmundis, C, additional, and Della Rocca, D G, additional
- Published
- 2023
- Full Text
- View/download PDF
15. Diagnostic accuracy of smart gadgets/wearable devices in detecting atrial fibrillation in primary prevention: a meta-analysis
- Author
-
Vetta, G, primary, Magnocavallo, M, additional, Parlavecchio, A, additional, Caminiti, R, additional, Polselli, M, additional, Sorgente, A, additional, Pannone, L, additional, Chierchia, G B, additional, Rossi, P, additional, Bianchi, S, additional, Natale, A, additional, De Asmundis, C, additional, and Della Rocca, D G, additional
- Published
- 2023
- Full Text
- View/download PDF
16. Diagnostic accuracy of smartwatch in detecting atrial fibrillation: a systemic review and meta-analysis
- Author
-
Vetta, G, primary, Magnocavallo, M, additional, Parlavecchio, A, additional, Caminiti, R, additional, Polselli, M, additional, Sorgente, A, additional, Pannone, L, additional, Chierchia, G B, additional, Rossi, P, additional, Bianchi, S, additional, Natale, A, additional, De Asmundis, C, additional, and Della Rocca, D G, additional
- Published
- 2023
- Full Text
- View/download PDF
17. Left atrial appendage anatomical changes following radiofrequency-based ostial isolation
- Author
-
Della Rocca, D, primary, Magnocavallo, M, additional, Gianni, C, additional, Mohanty, S, additional, Vetta, G, additional, Bassiouny, M, additional, Pannone, L, additional, De Asmundis, C, additional, Lavalle, C, additional, Chierchia, G B, additional, Di Biase, L, additional, Burkhardt, J D, additional, Gallinghouse, G, additional, Horton, R, additional, and Natale, A, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Electrophysiological findings in patients undergoing left atrial appendage occlusion following previous electrical isolation
- Author
-
Della Rocca, D, primary, Magnocavallo, M, additional, Gianni, C, additional, Mohanty, S, additional, Vetta, G, additional, Bassiouny, M, additional, Al-Ahmad, A, additional, Horton, R, additional, Lavalle, C, additional, Burkhardt, D, additional, Gallinghouse, J, additional, De Asmundis, C, additional, Chierchia, G B, additional, Di Biase, L, additional, and Natale, A, additional
- Published
- 2023
- Full Text
- View/download PDF
19. 3D intracardiac echocardiography for left atrial appendage sizing and percutaneous occlusion guidance
- Author
-
Della Rocca, D, primary, Magnocavallo, M, additional, Gianni, C, additional, Mohanty, S, additional, Vetta, G, additional, Lavalle, C, additional, Santangeli, P, additional, De Asmundis, C, additional, Chierchia, G B, additional, Burkhardt, J D, additional, Di Biase, L, additional, Lakkireddy, D J, additional, Al-Ahmad, A, additional, Horton, R P, additional, and Natale, A, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Ergonomic and compact armrest of agricultural tractors – Innovative methods to design an ergonomic armrest
- Author
-
Campanella, C., primary, Huber, K., additional, Monacelli, G., additional, Ungaretti, L., additional, D’Orazio, M., additional, Scotto di vetta, G., additional, Peruzzini, M., additional, and Grandi, F., additional
- Published
- 2019
- Full Text
- View/download PDF
21. P26 “FUNCTION FOLLOWS FORM”: THE ROLE OF THE CARDIAC MAGNETIC RESONANCE IN THE ARRHYTHMIC RISK STRATIFICATION IN PATIENTS WITH CARDIAC SARCOIDOSIS
- Author
-
Vetta, G, primary, Magnocavallo, M, additional, Della Rocca, D, additional, Mariani, M, additional, Piro, A, additional, Fedele, F, additional, Natale, A, additional, Chimenti, C, additional, and Lavalle, C, additional
- Published
- 2022
- Full Text
- View/download PDF
22. P94 LOWER RATE OF MAJOR BLEEDING IN HIGH–RISK PATIENTS UNDERGOING LEFT ATRIAL APPENDAGE OCCLUSION: A PROPENSITY MATCHED COMPARISON WITH DIRECT ORAL ANTICOAGULATION
- Author
-
Magnocavallo, M, primary, Della Rocca, D, additional, Vetta, G, additional, Lavalle, C, additional, Mariani, M, additional, Schiavone, M, additional, Carola, G, additional, Mohanty, S, additional, Bassiouny, M, additional, Forleo, G, additional, Burkhardt, D, additional, Al–Ahmad, A, additional, Gallinghouse, J, additional, Horton, R, additional, Lakireddy, D, additional, Di Biase, L, additional, and Natale, A, additional
- Published
- 2022
- Full Text
- View/download PDF
23. P4 LEFT ATRIAL APPENDAGE ANATOMICAL CHANGES FOLLOWING RADIOFREQUENCY–BASED OSTIAL ISOLATION
- Author
-
Magnocavallo, M, primary, Della Rocca, D, additional, Lavalle, C, additional, Vetta, G, additional, Mariani, M, additional, Carola, G, additional, Mohanty, S, additional, Fengwei, Z, additional, Tarantino, N, additional, Aung, L, additional, Alisara, A, additional, Xiaodong, Z, additional, Bassiouny, M, additional, Gallinghouse, J, additional, Burkhardt, D, additional, Al–Ahmad, A, additional, Rodney, H, additional, Di Biase, L, additional, and Natale, A, additional
- Published
- 2022
- Full Text
- View/download PDF
24. C66 LONG TERM FOLLOW–UP OF PATIENTS WITH BIOPSY– PROVEN DIAGNOSIS OF MYOCARDITIS AND VENTRICULAR ARRHYTHMIAS
- Author
-
Lavalle, C, primary, Magnocavallo, M, additional, Mariani, M, additional, Vetta, G, additional, Della Rocca, D, additional, Alfarano, M, additional, Piro, A, additional, Natale, A, additional, Fedele, F, additional, Vizza, D, additional, Frustaci, A, additional, and Chimenti, C, additional
- Published
- 2022
- Full Text
- View/download PDF
25. Impairment of LA strain and LV myocardial work in Ph+ Chronic myeloid leukaemia patients treated with TKis
- Author
-
Parlavecchio, A, primary, Caminiti, R, additional, Vetta, G, additional, Pelaggi, G, additional, Lofrumento, F, additional, Vinciguerra, P, additional, Parisi, F, additional, Demurtas, E, additional, Licordari, R, additional, Cusma, M, additional, Manganaro, R, additional, Micari, A, additional, Di Bella, G, additional, Carerj, S, additional, and Zito, C, additional
- Published
- 2022
- Full Text
- View/download PDF
26. Wasted myocardial work may affect left ventricular remodelling occurrence after primary percutaneous coronary revascularization
- Author
-
Caminiti, R, primary, Vetta, G, additional, Parlavecchio, A, additional, Pelaggi, G, additional, Lofrumento, F, additional, Licordari, R, additional, Cusma, M, additional, Manganaro, R, additional, Pucci, M, additional, Radano, I, additional, Citro, R, additional, Carerj, S, additional, Di Bella, G, additional, and Zito, C, additional
- Published
- 2022
- Full Text
- View/download PDF
27. Prediction of early left ventricular recovery and adverse remodelling in patients with acute myocardial infarction: the role of non-invasive myocardial work evaluation
- Author
-
Caminiti, R, primary, Vetta, G, additional, Parlavecchio, A, additional, Marano, G, additional, Ruggieri, C, additional, Citro, R, additional, Radano, I, additional, Pucci, M, additional, Di Bella, G, additional, Micari, A, additional, Carerj, S, additional, and Zito, C, additional
- Published
- 2021
- Full Text
- View/download PDF
28. P454Validation of a new LVH ECG criterion in a single center wide population
- Author
-
Ricciardi, D, primary, Vetta, G, additional, Nenna, A, additional, Migliaro, G, additional, Calabrese, V, additional, Venditti, A, additional, Urbano, M, additional, Picarelli, F, additional, Ragni, L, additional, Vetta, F, additional, Melfi, R, additional, Mangiacapra, F, additional, Di Belardino, N, additional, and Di Sciascio, G, additional
- Published
- 2018
- Full Text
- View/download PDF
29. The protection of the human embryo in the new Gasparri proposed law
- Author
-
P. Grimaldi, A. D'Aloia, L. Montano, G. Falco, S. Guida, S. Landini, L. Valle, F. Di Lella, M. Rizzuti, F. Ferretti, P. Arpaia, A. E. Rizzoli, R. Montanari, R. Presta, M. A. Ciocia, E. Palmerini, A. Bertolini, F. Battaglia, G. Di vetta, P. Haselager, L. Casalini, F. Cesareo, A. Mollo, D. Napolitano, L. M. Sicca, M. Galli, F. Flammini, S. Orlando, V. Cuocci, G. Capilli, L. Viola, G. D'Aietti, A. I. della Valle, R. Paura, L. Gatt, I. A. Caggiano, M. C. Gaeta, E. Troisi, L. Aulino, L. Izzo, D. S. D'Aloia, A. Di Forno, F. Ribezzo, L. Vizzoni., P. Grimaldi, A. D'Aloia, L. Montano, G. Falco, S. Guida, S. Landini, L. Valle, F. Di Lella, M. Rizzuti, F. Ferretti, P. Arpaia, A.E. Rizzoli, R. Montanari, R. Presta, M.A. Ciocia, E. Palmerini, A. Bertolini, F. Battaglia, G. Di vetta, P. Haselager, L. Casalini, F. Cesareo, A. Mollo, D. Napolitano, L.M. Sicca, M. Galli, F. Flammini, S. Orlando, V. Cuocci, G. Capilli, L. Viola, G. D'Aietti, A.I. della Valle, R. Paura, L. Gatt, I.A. Caggiano, M.C. Gaeta, E. Troisi, L. Aulino, L. Izzo, D.S. D'Aloia, A. Di Forno, F. Ribezzo, L. Vizzoni., L. Gatt, M.C. Gaeta, L. Aulino, Grimaldi, P., D'Aloia, A., Montano, L., Falco, G., Guida, S., Landini, S., Valle, L., Di Lella, F., Rizzuti, M., Ferretti, F., Arpaia, P., Rizzoli, A. E., Montanari, R., Presta, R., Ciocia, M. A., Palmerini, E., Bertolini, A., Battaglia, F., Di vetta, G., Haselager, P., Casalini, L., Cesareo, F., Mollo, A., Napolitano, D., Sicca, L. M., Galli, M., Flammini, F., Orlando, S., Cuocci, V., Capilli, G., Viola, L., D'Aietti, G., della Valle, A. I., Paura, R., Gatt, L., Caggiano, I. A., Gaeta, M. C., Troisi, E., Aulino, L., Izzo, L., D'Aloia, D. S., Di Forno, A., Ribezzo, F., and Vizzoni., L.
- Subjects
Vulnerable subjects, reproductive technologies, human embryos, Gasparri law proposal - Abstract
With the bill n. 165 Senator Gasparri returns to the art. 1 c.c. presenting a new proposal – new compared to those dating back to the 16th and 17th legislatures – entitled “Amendment to art. 1 of the civil code in the matter of recognition of the legal capacity of the conceived child”; precisely asking that the recognition of the legal capacity of the fetus already take place at the time of conception and not only after birth, as instead today enshrined in art. 1 of our civil code. A bill that gives the opportunity to reflect, once again, on the questions on the specific theme of the protection of the human embryo and therefore: What is the embryo? What rights should he be recognized? But above all since when should they be recognized?
- Published
- 2023
30. Focal Pulsed Field Ablation for Premature Ventricular Contractions: A Multicenter Experience.
- Author
-
Della Rocca DG, Cespón-Fernández M, Keelani A, Raffa S, Pannone L, Almorad A, Ströker E, Borisov G, Bala G, Sieira J, Vetta G, Alothman O, Sorgente A, Audiat C, Overeinder I, Frommhold M, Del Monte A, La Meir M, Natale A, Chierchia GB, Geller JC, de Asmundis C, and Sarkozy A
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Treatment Outcome, Aged, Electrophysiologic Techniques, Cardiac, Time Factors, Adult, Action Potentials, Heart Rate, Ventricular Premature Complexes physiopathology, Ventricular Premature Complexes surgery, Ventricular Premature Complexes diagnosis, Catheter Ablation methods, Feasibility Studies
- Abstract
Background: Pulsed field ablation (PFA) is a novel technology for catheter-based atrial arrhythmia treatment. Evidence of its application for ventricular arrhythmia ablation is still limited. In this study, we describe the feasibility and efficacy of focal PFA for premature ventricular contraction (PVC) ablation., Methods: A prospective cohort of 20 patients referred for PVC ablation at 2 centers was enrolled, regardless of the presence of structural heart disease, PVC morphology, or previous ablation attempts. All procedures were performed using the CENTAURI System in combination with contact force sensing catheters and 3-dimensional electroanatomical mapping systems. Energy output and the number of applications were left to the operator's discretion., Results: Eleven (55%) procedures were conducted under general anesthesia, 6 (30%) under deep sedation, and 3 (15%) under light sedation. Muscular contraction was observed in one case (5%). Median procedural and fluoroscopy times were 95.5 and 6.55 minutes, respectively. The median number of PFA applications was 8 with a median contact force of 10 g . A statistically significant (76%) reduction was observed in mean peak-to-peak bipolar electrogram voltage before and after ablation (0.707 versus 0.098 mV; P =0.008). Ventricular irritative firing was observed in 11 (55%) patients after PFA. The median follow-up was 120 days. Acute procedural success was achieved in 17 of 20 (85% [95% CI, 0.70-1]) patients. Two of the patients with procedural failure had late success with >80% clinical PVC burden suppression during follow-up, and 2 of 17 patients with acute success had late PVC recurrence, which accounts for a total of 17 of 20 (85% [95% CI, 0.70-1]) patients with chronic success. Transient ST-segment depression occurred in 1 patient, and the right bundle branch block was induced in 2 others (permanently only in one case)., Conclusions: PVC ablation using a focal PFA is feasible, effective, and safe, with promising acute and long-term results in several ventricular locations. Irritative firing is frequently observed. Coronary evaluation should be considered when targeting the outflow tract., Competing Interests: Dr La Meir is a consultant for AtriCure. Dr Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr de Asmundis received research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus and compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, Acutus Medical, and Daiichi Sankyo. Dr Sorgente is a consultant for Biosense Webster and Abbott and received compensation for teaching purposes from Medtronic, Biotronik, and Microport. The other authors report no conflicts.
- Published
- 2024
- Full Text
- View/download PDF
31. Coronary Vasospasm During Isthmus Pulsed Field Ablation With Wide Area Focal Catheter.
- Author
-
Del Monte A, Della Rocca DG, Pannone L, Vetta G, Doundoulakis I, Cespón Fernández M, Marcon L, Monaco C, Sorgente A, Bala G, Ströker E, Sieira J, Almorad A, Sarkozy A, de Asmundis C, and Chierchia GB
- Published
- 2024
- Full Text
- View/download PDF
32. Ranolazine Unveiled: Rediscovering an Old Solution in a New Light.
- Author
-
De Santis GA, De Ferrari T, Parisi F, Franzino M, Molinero AE, Di Carlo A, Pistelli L, Vetta G, Parlavecchio A, Torre M, Parollo M, Mansi G, Tamborrino PP, Canu A, Grifoni G, Segreti L, Di Cori A, Viani SM, and Zucchelli G
- Abstract
Ranolazine is an anti-anginal medication that has demonstrated antiarrhythmic properties by inhibiting both late sodium and potassium currents. Studies have shown promising results for ranolazine in treating both atrial fibrillation and ventricular arrhythmias, particularly when used in combination with other medications. This review explores ranolazine's mechanisms of action and its potential role in cardiac arrhythmias treatment in light of previous clinical studies.
- Published
- 2024
- Full Text
- View/download PDF
33. Long-Term Results Following Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis: A Systematic Review and Meta-Analysis of Randomized Trials.
- Author
-
Caminiti R, Ielasi A, Vetta G, Parlavecchio A, Rocca DGD, Glauber M, Tespili M, Vizzari G, and Micari A
- Abstract
Transcatheter aortic valve replacement (TAVR) is a safe and effective treatment option for patients with severe aortic stenosis at intermediate or high surgical risk. Results after TAVR in low-risk patients are very encouraging at midterm follow-up, whereas limited long-term (≥3 year) data are available in this subset of patients. This meta-analysis aims to compare the long-term follow-up after TAVR versus surgical aortic valve replacement (SAVR) in low-risk patients. We searched databases up to July 7, 2024 for randomized clinical trials comparing TAVR versus SAVR in low-risk patients (defined as Society of Thoracic Surgeons Predicted Risk of Mortality score <4%) (PROSPERO ID: CRD42023480495). Primary outcome analyzed was all-cause death at a minimum of 3 years of follow-up. The secondary outcomes were cardiovascular death, disabling stroke, myocardial infarction, aortic valve reintervention, endocarditis, new-onset atrial fibrillation, permanent pacemaker implantation, and bioprosthetic valve failure. A total of 3 randomized clinical trials with 2,644 patients (TAVR n = 1,371 patients; SAVR n = 1,273 patients) were included. The follow-up time was 6 ± 2.9 years. TAVR resulted noninferior to SAVR for all-cause death (risk ratio [RR] 0.99, 95% confidence interval [CI] 0.84 to 1.17, p = 0.89, I
2 = 28%), cardiovascular death (RR 0.94, 95% CI 0.76 to 1.15, p = 0.54, I2 = 0%), myocardial infarction (RR 1.06, 95% CI 0.71 to 1.57, p = 0.79, I2 = 61%), aortic valve reintervention, endocarditis, and bioprosthetic valve failure. New-onset atrial fibrillation was more common in the SAVR group, whereas permanent pacemaker implantation was more common in the TAVR group. In conclusion, our meta-analysis showed that TAVR is associated with similar long-term outcomes compared with SAVR in selected low-risk patients., Competing Interests: Declaration of competing interest The authors have no competing interests to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
34. Correlations of ventricular fibrillation and monomorphic ventricular tachycardia with SCN5A mutations and other clinical variables in Brugada syndrome.
- Author
-
Pannone L, Bisignani A, Osei R, Gauthey A, Sorgente A, Monaco C, Della Rocca DG, Del Monte A, Strazdas A, Mojica J, Al Housari M, Miraglia V, Mouram S, Vetta G, Paparella G, Doundoulakis I, Overeinder I, Bala G, Almorad A, Ströker E, Pappaert G, Sieira J, de Ravel T, La Meir M, Sarkozy A, Brugada P, Chierchia GB, Van Dooren S, and de Asmundis C
- Abstract
Competing Interests: Disclosures A.So. received research grants from Daiichi-Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. M.L.M. is a consultant for AtriCure. A.S. is a consultant for Biosense Webster and Medtronic and received speaker fees from Biosense Webster, Biotronik, Pfizer, and MicroPort. G.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik. and Boston Scientific. C.d.A. receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, MicroPort, Boston Scientific. and AtriCure; and received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, MicroPort, Boston Scientific, AtriCure, and Daiichi Sankyo. The remaining authors have no conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
35. Distance-dependent neuromodulation effect during thermal ablation for atrial fibrillation.
- Author
-
Nakasone K, Tanaka K, Del Monte A, Della Rocca DG, Pannone L, Mouram S, Cespón-Fernández M, Doundoulakis I, Marcon L, Audiat C, Vetta G, Scacciavillani R, Overeinder I, Bala G, Sorgente A, Sieira J, Almorad A, Fukuzawa K, Hirata KI, Brugada P, Sarkozy A, Chierchia GB, de Asmundis C, and Ströker E
- Abstract
Introduction: Thermal atrial fibrillation (AF) ablation exerts an additive treatment effect on the cardiac autonomic nervous system (CANS). This effect is mainly reported during ablation of the right superior pulmonary vein (RSPV), modulating the right anterior ganglionated plexus (RAGP), which contains parasympathetic innervation to the sinoatrial node in the epicardial fat pad between RSPV and superior vena cava (SVC). However, a variable response to neuromodulation after ablation is observed, with little to no effect in some patients. Our objective was to assess clinical and anatomic predictors of thermal ablation-induced CANS changes, as assessed via variations in heart rate (HR) postablation., Methods: Consecutive paroxysmal AF patients undergoing first-time PV isolation by the cryoballoon (CB) or radiofrequency balloon (RFB) within a 12-month time frame and with preprocedural cardiac computed tomography (CT), were evaluated. Preablation and 24-h postablation electrocardiograms in sinus rhythm were collected and analyzed to assess HR. Anatomic evaluation by CT included the measurement of the shortest distance between the SVC and RSPV ostium (RSPV-SVC distance)., Results: A total of 97 patients (CB, n = 50 vs. RFB, n = 47) were included, with similar baseline characteristics between both groups. A significant HR increase postablation (ΔHR ≥ 15 bpm) occurred in a total of 37 patients (38.1%), without difference in number of patients between both thermal ablation technologies (CB, 19 [51%]), RFB, 18 [49%]). Independent predictors for increased HR were RSPV-SVC distance (odds ratio [OR]: 0.49, CI: 0.34-0.71, p value < .001), and age (OR: 0.94, CI: 0.89-0.98, p value = .003)., Conclusions: Thermal balloon-based PV isolation influences the CANS through its effect on the RAGP, especially in younger patients and patients with shorter RSPV-SVC distance., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
36. Contrast-enhanced excimer laser stepwise approach during PCI for resistant coronary lesions.
- Author
-
Vizzari G, Caminiti R, Ielasi A, Vetta G, Parlavecchio A, Mazzone P, Sacchetta G, Magnocavallo M, Della Rocca DG, Siviglia M, Versace AG, Contarini M, and Micari A
- Subjects
- Humans, Retrospective Studies, Male, Female, Aged, Treatment Outcome, Middle Aged, Italy, Coronary Angiography, Predictive Value of Tests, Time Factors, Percutaneous Coronary Intervention instrumentation, Percutaneous Coronary Intervention adverse effects, Stents, Risk Factors, Lasers, Excimer therapeutic use, Atherectomy, Coronary adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Contrast Media administration & dosage
- Abstract
Background: The treatment of resistant coronary lesions (RCL) is a great challenge for interventional cardiologists. The excimer laser coronary atherectomy (ELCA) is a plaque modification tool based on a main mechanism of photomechanical effect leading to mechanical disruption of the plaque. Contrast dye injection during laser delivery has demonstrated to enhance its power., Aim: To evaluate the effectiveness and safety of the contrast-enhanced ELCA by a stepwise approach in the treatment of RCLs., Methods: We retrospectively examined consecutive patients undergoing contrast-enhanced ELCA-assisted PCI between 2018 and 2021 at two Italian sites. RCLs were defined as novo or in-stent undilatable/uncrossable with conventional balloons (SC/NC balloon). The primary endpoint was ELCA technical success defined as the laser catheter crossing the entire length of the target lesion established by angiographic evidence of the catheter tip in the artery distal to the stenosis., Results: We enrolled 114 patients who underwent contrast-enhanced ELCA-assisted PCI: 58% of the patients had acute coronary syndrome while the left anterior descending artery was the target vessel in 42.1% of cases. The target lesion was most commonly in-stent (56.2%). The 0.9 mm ELCA catheter tip was employed in 89.5% of cases. The most used frequency/fluency profile was 70/70 (39.5%). The use of contrast-enhanced ELCA was associated with high technical, procedural, and clinical success rates (97.4%, 93.7%, and 90.1%, respectively)., Conclusions: The contrast-enhanced ELCA seems to be a safe and effective treatment option for the management of both de novo and in-stent-resistant coronary lesions., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
37. Lower rate of major bleeding in very high risk patients undergoing left atrial appendage occlusion: A propensity score-matched comparison with direct oral anticoagulant.
- Author
-
Magnocavallo M, Della Rocca DG, Vetta G, Mohanty S, Gianni C, Polselli M, Rossi P, Parlavecchio A, Fazia MV, Guarracini F, De Vuono F, Bisignani A, Pannone L, Raposeiras-Roubín S, Lochy S, Cauti FM, Burkhardt JD, Boveda S, Sarkozy A, Sorgente A, Bianchi S, Chierchia GB, de Asmundis C, Al-Ahmad A, Di Biase L, Horton RP, and Natale A
- Subjects
- Humans, Male, Female, Aged, Administration, Oral, Risk Assessment methods, Hemorrhage chemically induced, Hemorrhage epidemiology, Stroke prevention & control, Stroke etiology, Stroke epidemiology, Risk Factors, Follow-Up Studies, Prospective Studies, Incidence, Treatment Outcome, Thromboembolism prevention & control, Thromboembolism etiology, Thromboembolism epidemiology, Aged, 80 and over, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Appendage surgery, Propensity Score, Anticoagulants administration & dosage, Anticoagulants therapeutic use
- Abstract
Background: Long-term oral anticoagulation is the mainstay therapy for thromboembolic (TE) prevention in patients with atrial fibrillation. However, left atrial appendage occlusion (LAAO) could be a safe alternative to direct oral anticoagulants (DOACs) in patients with a very high TE risk profile., Objective: The purpose of this study was to compare the safety and efficacy of LAAO vs DOACs in patients with atrial fibrillation at very high stroke risk (CHA
2 DS2 -VASc [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65-74 years, sex category] score ≥ 5)., Methods: Data from patients with CHA2 DS2 -VASc score ≥ 5 were extracted from a prospective multicenter database. To attenuate the imbalance in covariates between groups, propensity score matching was used (covariates: CHA2 DS2 -VASc and HAS-BLED [hypertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol] scores), which resulted in a matched population of 277 patients per group. The primary end point was a composite of cardiovascular death, TE events, and clinically relevant bleeding during follow-up., Results: Of 2381 patients, 554 very high risk patients were included in the study (mean age 79 ± 7 years; CHA2 DS2 -VASc score 5.8 ± 0.9; HAS-BLED score 3.0 ± 0.9). The mean follow-up duration was 25 ± 11 months. A higher incidence of the composite end point was documented with DOACs compared with LAAO (14.9 events per 100 patient-years in the DOAC group vs 9.4 events per 100 patient-years in the LAAO group; P = .03). The annualized clinically relevant bleeding risk was higher with DOACs (6.3% vs 3.2%; P = .04), while the risk of TE events was not different between groups (4.1% vs 3.2%; P = .63)., Conclusion: In high-risk patients, LAAO had a similar stroke prevention efficacy but a significantly lower risk of clinically relevant bleeding when compared with DOACs. The clinical benefit of LAAO became significant after 18 months of follow-up., Competing Interests: Disclosures Dr Burkhardt is a consultant for Biosense Webster and Stereotaxis. Dr Chierchia has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr de Asmundis has received research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus Medical and compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, Acutus Medical, and Daiichi Sankyo. Dr Di Biase is a consultant for Biosense Webster, Boston Scientific, Stereotaxis, and St. Jude Medical. Dr Di Biase has received speaker honoraria/travel support from Medtronic, Bristol Meyers Squibb, Pfizer, and Biotronik. Dr Natale has received speaker honoraria from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik, and Medtronic and is a consultant for Biosense Webster, St. Jude Medical, and Janssen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
38. MI2AMI-CS: A meta-analysis comparing Impella and IABP outcomes in Acute Myocardial Infarction-related Cardiogenic Shock.
- Author
-
De Ferrari T, Pistelli L, Franzino M, Molinero AE, De Santis GA, Di Carlo A, Vetta G, Parlavecchio A, Fimiani L, Picci A, Certo G, Parisi F, and Venuti G
- Subjects
- Humans, Treatment Outcome, Randomized Controlled Trials as Topic methods, Shock, Cardiogenic therapy, Shock, Cardiogenic mortality, Shock, Cardiogenic etiology, Intra-Aortic Balloon Pumping methods, Heart-Assist Devices, Myocardial Infarction complications, Myocardial Infarction mortality
- Abstract
Background: Cardiogenic Shock (CS) complicating acute myocardial infarction (AMI) poses a significant mortality risk, suggesting the opportunity to implement effective mechanical circulatory support strategies. The comparative efficacy of Intra-Aortic Balloon Pump (IABP) and Impella in managing CS-AMI remains a subject of investigation., Objective: This meta-analysis aims to evaluate the comparative effectiveness of Impella and IABP in managing CS-AMI, exploring mortality and adverse events., Methods: A systematic search of major databases from inception to November 2023 identified eight studies, comprising 10,628 patients, comparing Impella and IABP in CS-AMI. Retrospective studies (preferably Propensity-matched) and Randomized Clinical Trials (RCTs) were included., Results: Impella use exhibited significantly higher mortality (57% vs. 46%; OR: 1.44, 95% CI: 1.29-1.60; p < 0.001) and major bleeding (30% vs 15%; OR: 2.93, 95% CI: 1.67-5.13; p < 0.001)., Conclusions: In unselected CS-AMI patients, Impella usage is associated with significantly higher mortality and major bleeding., Competing Interests: Declaration of competing interest Authors have no conflict of interest to declare., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Drug-coated balloon versus drug-eluting stent for treating de novo large vessel coronary artery disease: a systematic review and meta-analysis of 13 studies involving 2888 patients.
- Author
-
Caminiti R, Vizzari G, Ielasi A, Vetta G, Parlavecchio A, Della Rocca DG, Montonati C, Pellegrini D, Pellicano M, Tespili M, and Micari A
- Abstract
Introduction: Drug-coated balloon (DCB) is an established treatment option for in-stent restenosis and small vessel, de novo, coronary artery disease (CAD). Although the use of this tool is increasing in everyday practice, data regarding performance in the treatment of de novo, large vessel CAD (LV-CAD) is still lacking. A systematic review and meta-analysis were conducted to evaluate the efficacy and safety of DCB versus drug-eluting stent (DES) in this setting., Methods: A comprehensive literature search was performed including Medline, Embase, and Cochrane electronic databases up to January 24, 2024, for studies which compared the efficacy and safety of DCB versus DES in the treatment of de novo lesions in large vessels (≥ 2.5 mm), reporting at least one clinical outcome of interest (PROSPERO ID: CRD42023470417). The analyzed outcomes were cardiovascular death (CVD), myocardial infarction (MI), target lesion revascularization (TLR), all-cause death (ACD), and late lumen loss (LLL) at follow-up. The effect size was estimated using a random effects model as risk ratio (RR) and mean difference (MD) and relative 95% confidence interval (CI)., Results: A total of 13 studies (6 randomized controlled trials and 7 observational studies) involving 2888 patients (DCB n = 1334; DES n = 1533) with de novo LV-CAD were included in this meta-analysis following our inclusion criteria. No differences were observed between DCB and DES in terms of CVD (RR 0.49; 95% CI [0.23-1.03]; p = 0.06), MI (RR 0.48; 95% CI [0.16-1.45]; p = 0.89), TLR (RR 0.73; 95% CI [0.40-1.34]; p = 0.32), ACD (RR 0.78; 95% CI [0.57-1.07]; p = 0.12), and LLL (MD - 0.14; 95% CI [- 0.30 to 0.02]; p = 0.10) at follow-up. DES proved a higher mean acute gain versus DCB [1.94 (1.73, 2.14) vs 1.31 (1.02, 1.60); p = 0.0006]., Conclusion: Our meta-analysis showed that DCB PCI might provide a promising option for the management of selected, de novo LV-CAD compared to DES. However, more focused RCTs are needed to further prove the benefits of a "metal-free" strategy in this subset of CAD., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
40. Percutaneous Coronary Intervention before or after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis Involving 1531 Patients.
- Author
-
Caminiti R, Ielasi A, Vetta G, Parlavecchio A, Della Rocca DG, Pellegrini D, Pellicano M, Montonati C, Mancini N, Carciotto G, Ajello M, Iuvara G, Costa F, Laterra G, Barbanti M, Ceresa F, Patanè F, Micari A, and Vizzari G
- Abstract
Background: The optimal timing to perform percutaneous coronary interventions (PCIs) in patients undergoing transcatheter aortic valve replacement (TAVR) is not well established. In this meta-analysis, we aimed to compare the outcomes of patients undergoing PCI before versus after TAVR. Methods: A comprehensive literature search was performed including Medline, Embase, and Cochrane electronic databases up to 5 April 2024 for studies that compared PCI before and after TAVR reporting at least one clinical outcome of interest (PROSPERO ID: CRD42023470417). The analyzed outcomes were mortality, stroke, and myocardial infarction (MI) at follow-up. Results: A total of 3 studies involving 1531 patients (pre-TAVR PCI n = 1240; post-TAVR PCI n = 291) were included in this meta-analysis following our inclusion criteria. Mortality was higher in the pre-TAVR PCI group (OR: 2.48; 95% CI: 1.19-5.20; p = 0.02). No differences were found between PCI before and after TAVR for the risk of stroke (OR: 3.58; 95% CI: 0.70-18.15; p = 0.12) and MI (OR: 0.66; 95% CI: 0.30-1.42; p = 0.29). Conclusions: This meta-analysis showed in patients with stable CAD undergoing TAVR that PCI after TAVR is associated with lower mortality compared with PCI before TAVR.
- Published
- 2024
- Full Text
- View/download PDF
41. Pulsed field ablation of the right superior pulmonary vein prevents vagal responses via anterior right ganglionated plexus modulation.
- Author
-
Del Monte A, Della Rocca DG, Pannone L, Vetta G, Cespón Fernández M, Marcon L, Doundoulakis I, Mouram S, Audiat C, Zeriouh S, Monaco C, Al Housari M, Betancur A, Mené R, Iacopino S, Sorgente A, Bala G, Ströker E, Sieira J, Almorad A, Sarkozy A, Boveda S, de Asmundis C, and Chierchia GB
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Heart Conduction System physiopathology, Aged, Treatment Outcome, Ganglia, Autonomic physiopathology, Ganglia, Autonomic surgery, Follow-Up Studies, Pulmonary Veins surgery, Atrial Fibrillation surgery, Atrial Fibrillation physiopathology, Catheter Ablation methods, Heart Rate physiology, Vagus Nerve physiopathology, Vagus Nerve physiology
- Abstract
Background: Pulsed field ablation (PFA) is selective for the myocardium. However, vagal responses and reversible effects on ganglionated plexi (GP) are observed during pulmonary vein isolation (PVI). Anterior-right GP ablation has been proven to effectively prevent vagal responses during radiofrequency-based PVI., Objective: The purpose of this study was to test the hypothesis that PFA-induced transient anterior-right GP modulation when targeting the right superior pulmonary vein (RSPV) before any other pulmonary veins (PVs) may effectively prevent intraprocedural vagal responses., Methods: Eighty consecutive paroxysmal atrial fibrillation patients undergoing PVI with PFA were prospectively included. In the first 40 patients, PVI was performed first targeting the left superior pulmonary vein (LSPV-first group). In the last 40 patients, RSPV was targeted first, followed by left PVs and right inferior PV (RSPV-first group). Heart rate (HR) and extracardiac vagal stimulation (ECVS) were evaluated at baseline, during PVI, and postablation to assess GP modulation., Results: Vagal responses occurred in 31 patients (78%) in the LSPV-first group and 5 (13%) in the RSPV-first group (P <.001). Temporary pacing was needed in 14 patients (35%) in the LSPV-first group and 3 (8%) in the RSPV-first group (P = .003). RSPV isolation was associated with similar acute HR increase in the 2 groups (13 ± 11 bpm vs 15 ± 12 bpm; P = .3). No significant residual changes in HR or ECVS response were documented in both groups at the end of the procedure compared to baseline (all P >.05)., Conclusion: PVI with PFA frequently induced vagal responses when initiated from the LSPV. Nevertheless, an RSPV-first approach promoted transient HR increase and reduced vagal response occurrence., Competing Interests: Disclosures Dr Sarkozy is a consultant for Biosense Webster, Medtronic, Biotronik, and MicroPort. Dr de Asmundis received research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; and compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, Acutus Medical, and Daiichi Sankyo. Dr Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. All other authors have no conflicts of interest to disclose., (Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. Success and complication rates of conduction system pacing: a meta-analytical observational comparison of left bundle branch area pacing and His bundle pacing.
- Author
-
Parlavecchio A, Vetta G, Coluccia G, Pistelli L, Caminiti R, Crea P, Ajello M, Magnocavallo M, Dattilo G, Foti R, Carerj S, Chierchia GB, de Asmundis C, Della Rocca DG, and Palmisano P
- Subjects
- Humans, Bundle-Branch Block therapy, Bundle of His physiopathology, Cardiac Pacing, Artificial methods, Cardiac Pacing, Artificial adverse effects, Observational Studies as Topic
- Abstract
Background: Left bundle branch area pacing (LBBAP) and His bundle pacing (HBP) are the main strategies to achieve conduction system pacing (CSP), but only observational studies with few patients have compared the two pacing strategies, sometimes with unclear results given the different definitions of the feasibility and safety outcomes. Therefore, we conducted a meta-analysis aiming to compare the success and complications of LBBAP versus HBP., Methods: We systematically searched the electronic databases for studies published from inception to March 22, 2023, and focusing on LBBAP versus HBP. The study endpoints were CSP success rate, device-related complications, CSP lead-related complications and non-CSP lead-related complications., Results: Fifteen observational studies enrolling 2491 patients met the inclusion criteria. LBBAP led to a significant increase in procedural success [91.1% vs 80.9%; RR: 1.15 (95% CI: 1.08-1.22); p < 0.00001] with a significantly lower complication rate [1.8% vs 5.2%; RR: 0.48 (95% CI: 0.29-0.78); p = 0.003], lead-related complications [1.1% vs 4.3%; RR: 0.38 (95% CI: 0.21-0.72); p = 0.003] and lead failure/deactivation [0.2% vs 3.9%; RR: 0.16 (95% CI: 0.07-0.35); p < 0.00001] than HBP. No significant differences were found between CSP lead dislodgement and non-CSP lead-related complications., Conclusion: This meta-analysis of observational studies showed a higher success rate of LBBAP compared to HBP with a lower incidence of complications., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
43. Catheter ablation as an adjunctive therapy to ICD implantation in Brugada syndrome.
- Author
-
Doundoulakis I, Chiotis S, Pannone L, Della Rocca DG, Sorgente A, Kordalis A, Scacciavillania R, Zafeiropoulos S, Marcon L, Vetta G, Pagkalidou E, Bala G, Almorad A, Ströker E, Sieira J, La Meir M, Brugada P, Tsiachris D, Sarkozy A, Chierchia GB, and de Asmundis C
- Abstract
Background: Brugada Syndrome (BrS) is a life-threatening cardiac arrhythmia disorder associated with an increased risk ventricular arrhythmias (VAs) and sudden cardiac death (SCD). Current management primarily relies on implantable cardioverter-defibrillators (ICDs), but patients may experience ICD shocks. Catheter ablation (CA) has emerged as a potential intervention to target the arrhythmogenic substrate. This systematic review aims to evaluate the safety and efficacy of catheter ablation in BrS patients., Methods and Results: Studies with BrS patients undergoing catheter ablation for VAs were included. 14 studies that involved a total population of 709 BrS patients, with catheter ablation performed in 528 of them, were included. Catheter ablation resulted in non-inducibility of VAs in 91% (95% CI: 83-99, I2 = 76%) and resolution of Type 1 ECG Brugada pattern in 88% (95% CI: 81-96.2, I2 = 91%) of the patients. After a mean follow-up of 30.7 months, 87% (95% CI: 80-94, I2 = 82%) of patients remained free from VAs. The incidence of VAs during follow-up was significantly lower in the ablation cohort in comparison to the group receiving only ICD therapy (OR = 0.03, 95% CI: 0.01-0.12, I2 = 0%)., Conclusion: Catheter ablation shows potential as a therapeutic approach to reduce VAs and improve outcomes in BrS patients. While further research with long follow-up period is required to confirm these findings, it represents a valuable tool as an add-on intervention to ICD implantation in BrS patients with high burden of VAs.Protocol registration: CRD42024506439., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
44. SCN5A gene variants and arrhythmic risk in Brugada syndrome: An updated systematic review and meta-analysis.
- Author
-
Doundoulakis I, Pannone L, Chiotis S, Della Rocca DG, Sorgente A, Tsioufis P, Del Monte A, Vetta G, Piperis C, Overeinder I, Bala G, Almorad A, Ströker E, Sieira J, La Meir M, Brugada P, Tsiachris D, Sarkozy A, Chierchia GB, and de Asmundis C
- Abstract
Background: A rare gene variant in SCN5A can be found in approximately 20%-25% of patients with Brugada syndrome (BrS)., Objective: The aim of this systematic review and meta-analysis was to evaluate the differences in clinical characteristics of BrS patients with and without SCN5A rare variants and the prognostic role of SCN5A for ventricular arrhythmias in BrS., Methods: PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were systematically searched from inception to January 2024 to identify all relevant studies. Studies were analyzed if they included patients diagnosed with BrS in whom genetic testing for SCN5A variants was performed and arrhythmic outcomes were reported., Results: A total of 17 studies with 3568 BrS patients, of whom 3030 underwent genetic testing for SCN5A variants, fulfilled the eligibility criteria and were included. Compared with SCN5A- patients, SCN5A+ BrS patients more frequently had spontaneous type 1 electrocardiogram, history of syncope, and documented arrhythmias. Furthermore, higher PQ and QRS intervals in SCN5A+ BrS patients compared with SCN5A- have been found. The pooled analysis demonstrated a significant association between the presence of SCN5A rare variants in BrS patients and the risk of major arrhythmic events, with a pooled odds ratio of 2.14 (95% confidence interval, 1.53-2.99; I
2 = 29%)., Conclusion: SCN5A+ BrS patients showed a worse clinical phenotype compared with SCN5A-. The pooled analysis demonstrated a significant association between SCN5A+ mutation status and the risk of major arrhythmic events in BrS patients., Competing Interests: Disclosures A.S. received research grants from Daiichi Sankyo and Bayer and has received speaker fees from Menarini and Bayer. M.L.M. is a consultant for AtriCure. P.B. received compensation for teaching purposes from Biotronik. G.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. C.dA. receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; and received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, and Acutus Medical Daiichi Sankyo. The remaining authors have nothing to disclose., (Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
45. Genetic Testing in Brugada Syndrome: A 30-Year Experience.
- Author
-
Pannone L, Bisignani A, Osei R, Gauthey A, Sorgente A, Monaco C, Della Rocca DG, Del Monte A, Strazdas A, Mojica J, Al Housari M, Miraglia V, Mouram S, Vetta G, Paparella G, Ramak R, Overeinder I, Bala G, Almorad A, Ströker E, Pappaert G, Sieira J, de Ravel T, La Meir M, Sarkozy A, Brugada P, Chierchia GB, Van Dooren S, and de Asmundis C
- Subjects
- Humans, Genetic Testing, Arrhythmias, Cardiac genetics, Mutation, Missense, NAV1.5 Voltage-Gated Sodium Channel genetics, Mutation, Brugada Syndrome diagnosis, Brugada Syndrome genetics
- Abstract
Background: A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis. The aim of this study is to define the diagnostic yield of a large gene panel with American College of Medical Genetics and Genomics variant classification and to assess prognosis of SCN5A and non-SCN5A variants., Methods: All patients with BrS, were prospectively enrolled in the Universitair Ziekenhuis Brussel registry between 1992 and 2022. Inclusion criteria for the study were (1) BrS diagnosis; (2) genetic analysis performed with a large gene panel; (3) classification of variants following American College of Medical Genetics and Genomics guidelines. Patients with a pathogenic/likely pathogenic variant in SCN5A were defined as SCN5A
+ . Patients with a reported variant in a non-SCN5A gene or with no reported variants were defined as patients with SCN5A- . All variants were classified as missense or predicted loss of function., Results: A total of 500 BrS patients were analyzed. A total of 104 patients (20.8%) were SCN5A+ and 396 patients (79.2%) were SCN5A- . A non-SCN5A gene variant was found in 75 patients (15.0%), of whom, 58 patients (77.3%) had a missense variant and 17 patients (22.7%) had a predicted loss of function variant. At a follow-up of 84.0 months, 48 patients (9.6%) experienced a ventricular arrhythmia (VA). Patients without any variant had higher VA-free survival, compared with carriers of a predicted loss of function variant in SCN5A+ or non-SCN5A genes. There was no difference in VA-free survival between patients without any variant and missense variant carriers in SCN5A+ or non-SCN5A genes. At Cox analysis, SCN5A+ or non-SCN5A predicted loss of function variant was an independent predictor of VA., Conclusions: In a large BrS cohort, the yield for SCN5A+ is 20.8%. A predicted loss of function variant carrier is an independent predictor of VA., Competing Interests: Disclosures Dr La Meir is consultant for Atricure. Dr Brugada received compensation for teaching purposes from Biotronik. Dr Battista Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, Acutus Medical. Dr de Asmundis receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; Dr de Asmundis received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, Atricure, Acutus Medical Daiichi Sankyo. The other authors report no conflicts.- Published
- 2024
- Full Text
- View/download PDF
46. Arrhythmic risk profile in mitral valve prolapse: A systematic review and metanalysis of 1715 patients.
- Author
-
Pistelli L, Vetta G, Parlavecchio A, Crea P, Parisi F, Magnocavallo M, Caminiti R, Frea S, Vairo A, Desalvo P, Faletti R, Gatti M, Dattilo G, Parollo M, Di Cori A, Bongiorni MG, De Santis G, Borgi M, Franzino M, Licordari R, Zucchelli G, Rocca GDD, and Giustetto C
- Subjects
- Humans, Risk Assessment, Risk Factors, Female, Male, Middle Aged, Aged, Arrhythmias, Cardiac physiopathology, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac etiology, Prognosis, Adult, Death, Sudden, Cardiac etiology, Death, Sudden, Cardiac prevention & control, Death, Sudden, Cardiac epidemiology, Mitral Valve diagnostic imaging, Mitral Valve physiopathology, Heart Rate, Action Potentials, Mitral Valve Prolapse physiopathology, Mitral Valve Prolapse diagnostic imaging, Mitral Valve Prolapse complications, Mitral Valve Prolapse diagnosis
- Abstract
Introduction: Mitral valve prolapse (MVP) is a common clinical condition in the general population. A subgroup of patients with MVP may experience ventricular arrhythmias and sudden cardiac death ("arrhythmic mitral valve prolapse" [AMVP]) but how to stratify arrhythmic risk is still unclear. Our meta-analysis aims to identify predictive factors for arrhythmic risk in patients with MVP., Methods: We systematically searched Medline, Cochrane, Journals@Ovid, Scopus electronic databases for studies published up to December 28, 2022 and comparing AMVP and nonarrhythmic mitral valve prolapse (NAMVP) for what concerns history, electrocardiographic, echocardiographic and cardiac magnetic resonance features. The effect size was estimated using a random-effect model as odds ratio (OR) and mean difference (MD)., Results: A total of 10 studies enrolling 1715 patients were included. Late gadolinium enhancement (LGE) (OR: 16.67; p = .005), T-wave inversion (TWI) (OR: 2.63; p < .0001), bileaflet MVP (OR: 1.92; p < .0001) and mitral anulus disjunction (MAD) (OR: 2.60; p < .0001) were more represented among patients with AMVP than in NAMVP. Patients with AMVP were shown to have longer anterior mitral leaflet (AML) (MD: 2.63 mm; p < .0001), posterior mitral leaflet (MD: 2.96 mm; p < .0001), thicker AML (MD: 0.49 mm; p < .0001), longer MAD length (MD: 1.24 mm; p < .0001) and higher amount of LGE (MD: 1.41%; p < .0001) than NAMVP. AMVP showed increased mechanical dispersion (MD: 8.04 ms; 95% confidence interval: 5.13-10.96; p < .0001) compared with NAMVP., Conclusions: Our meta-analysis proved that LGE, TWI, bileaflet MVP, and MAD are predictive factors for arrhythmic risk in MVP patients., (© 2023 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
47. Pericarditis prophylactic therapy after sinus node-sparing hybrid ablation for inappropriate sinus tachycardia/postural orthostatic sinus tachycardia.
- Author
-
de Asmundis C, Marcon L, Pannone L, Della Rocca DG, Lakkireddy D, Beaver TM, Brodt CR, Monaco C, Sorgente A, Audiat C, Vetta G, Ramak R, Overeinder I, Kronenberger R, Bala G, Almorad A, Ströker E, Sieira J, Sarkozy A, Brugada P, Chierchia GB, and La Meir M
- Abstract
Background: Pericarditis is the most common complication following hybrid sinus node-sparing ablation for inappropriate sinus tachycardia (IST)/postural orthostatic tachycardia syndrome (POTS)., Objective: The study sought to evaluate the association of prophylaxis therapy on the risk of symptomatic pericarditis following hybrid IST/POTS ablation., Methods: All consecutive patients undergoing to hybrid ablation of symptomatic IST/POTS refractory or intolerant to drugs were retrospectively analyzed. Pharmacological prophylaxis therapy was based on acetylsalicylic acid and colchicine started on the day of the ablation and continued for at least 3 months. The primary endpoint was occurrence of symptomatic pericarditis. The secondary endpoint was occurrence of pericarditis-related complications, including the following: duration of pericarditis >3 months, hospitalization for pericarditis, postpericardiectomy pleuro-pericarditis, and pericardiectomy., Results: A total of 220 patients undergone to hybrid IST/POTS ablation were included and 44 (20%) underwent prophylaxis therapy. Pericarditis occurred in 101 (45.9%) patients, with 97 (96%) in the first 5 days. At survival analysis, prophylaxis was associated with higher rate of freedom from pericarditis (81.9% vs 47.2%, log-rank P < .001). Pericarditis-related complications were low, occurring in 7 (3.2%) patients. There was no difference in pericarditis-related complications between the patients who underwent prophylaxis therapy and patients who did not. At Cox multivariate analysis, predictors of pericarditis were IST (vs POTS) (hazard ratio 0.61, 95% confidence interval0.39-0.99, P = .04) and prophylaxis therapy (hazard ratio 0.27, 95% confidence interval 0.13-0.55, P < .001)., Conclusion: In a large cohort of patients undergoing hybrid ablation for IST/POTS, a prophylaxis therapy with acetylsalicylic acid and colchicine was associated with a lower rate of symptomatic pericarditis., (© 2024 Heart Rhythm Society. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
48. Efficacy of Intravenous Nitrates for the Prevention of Coronary Artery Spasm During Pulsed Field Ablation of the Mitral Isthmus.
- Author
-
Menè R, Boveda S, Della Rocca DG, Sousonis V, Vetta G, Zeriouh S, Doundoulakis I, Betancur A, Benadel M, Combes N, Sarkozy A, Chierchia GB, de Asmundis C, Albenque JP, and Combes S
- Subjects
- Humans, Nitrates, Electrocardiography, Coronary Vasospasm etiology, Coronary Vasospasm prevention & control, Coronary Vasospasm surgery, Atrial Fibrillation surgery, Catheter Ablation adverse effects
- Abstract
Competing Interests: Disclosures Dr Boveda consults for Medtronic, Boston Scientific, MicroPort, and ZOLL. Dr Sarkozy is a consultant for Biosense Webster, Medtronic, Biotronik, and MicroPort. Dr Battista Chierchia received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. Dr de Asmundis receives research grants on behalf of the center from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus Medical and compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, LivaNova, Boston Scientific, AtriCure, Acutus Medical, and Daiichi Sankyo. Dr Albenque consults for Abbott and Volta Medical. The other authors report no conflicts.
- Published
- 2024
- Full Text
- View/download PDF
49. Redo procedures after sinus node sparing hybrid ablation for inappropriate sinus tachycardia/postural orthostatic sinus tachycardia.
- Author
-
de Asmundis C, Marcon L, Pannone L, Della Rocca DG, Lakkireddy D, Beaver TM, Brodt CR, Monaco C, Sorgente A, Audiat C, Vetta G, Ramak R, Overeinder I, Kronenberger R, Bala G, Almorad A, Ströker E, Sieira J, Sarkozy A, Brugada P, Chierchia GB, and La Meir M
- Subjects
- Humans, Sinoatrial Node, Heart Rate, Tachycardia, Sinus diagnosis, Tachycardia, Sinus surgery, Tachycardia, Sinus drug therapy, Catheter Ablation adverse effects, Catheter Ablation methods
- Abstract
Aims: A novel sinus node (SN) sparing hybrid ablation for inappropriate sinus node tachycardia (IST)/postural orthostatic tachycardia syndrome (POTS) has been demonstrated to be an effective and safe therapeutic option in patients with symptomatic drug-resistant IST/POTS. The aim of this study was to evaluate the long-term rate of redo procedures after hybrid IST ablation and procedural strategy, outcomes and safety of redo procedures., Methods and Results: All consecutive patients from 2015 to 2023 were prospectively enrolled in the UZ Brussel monocentric IST/POTS registry. They were analysed if the following inclusion criteria were fulfilled: 1) diagnosis of IST or POTS, 2) symptomatic IST/POTS refractory or intolerant to drugs, and 3) hybrid SN sparing ablation performed. The primary endpoint was redo procedure. The primary safety endpoint was pacemaker (PM) implantation. A total of 220 patients undergone to hybrid IST ablation were included, 185 patients (84.1%) were treated for IST and 61 patients (27.7%) for POTS.After a follow-up of 73.3 ± 16.2 months, 34 patients (15.4%) underwent a redo. A total of 23 patients (67.6%) had a redo for IST recurrence and 11 patients (32.4%) for other arrhythmias. Pacemaker implantation was performed in 21 patients (9.5%). Nine patients (4.1%) had no redo procedure and experienced sick sinus syndrome requiring a PM. Twelve patients (5.4%) received a PM as a shared therapeutic choice combined with SN ablation procedure., Conclusion: In a large cohort of patients the long-term free survival from redo procedure after hybrid IST ablation was 84.6% with a low PM implantation rate., Competing Interests: Conflict of interest: C.d.A receives research grants on behalf of the centre from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus; C.d.A. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Livanova, Boston Scientific, AtriCure, and Acutus Medical Daiichi Sankyo. A.S. received research grants from Daiichi Sankyo and Bayer; he has received speaker fees from Menarini and Bayer. PB received compensation for teaching purposes from Biotronik. G.C. received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. MLM is consultant for AtriCure. The remaining authors have nothing to disclose., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
50. Three-dimensional intracardiac echocardiography for left atrial appendage sizing and percutaneous occlusion guidance.
- Author
-
Della Rocca DG, Magnocavallo M, Gianni C, Mohanty S, Al-Ahmad A, Bassiouny M, Denora M, La Fazia VM, Lavalle C, Gallinghouse GJ, Santangeli P, Polselli M, Sarkozy A, Vetta G, Ahmed A, Sanchez JE, Pannone L, Chierchia GB, Tschopp DR, de Asmundis C, Di Biase L, Lakkireddy D, Burkhardt DJ, Horton RP, and Natale A
- Subjects
- Humans, Cross-Sectional Studies, Treatment Outcome, Cardiac Catheterization, Echocardiography, Transesophageal methods, Echocardiography methods, Atrial Appendage diagnostic imaging, Atrial Appendage surgery, Atrial Fibrillation diagnostic imaging, Atrial Fibrillation surgery, Atrial Fibrillation complications
- Abstract
Aims: Left atrial appendage (LAA) imaging is critical during percutaneous occlusion procedures. 3D-intracardiac echocardiography (ICE) features direct visualization of LAA from multiple cross-sectional planes at a time. We aimed at reporting procedural success of 3D-ICE-guided LAA occlusion and the correlation between pre-procedural transoesophageal echocardiography (TEE) and intraprocedural 3D-ICE for LAA sizing., Methods and Results: Among 274 patients undergoing left atrial appendage occlusion (LAAO) with a Watchman FLX, periprocedural ICE guidance was achieved via a commercially available 2D-ICE catheter (220 patients) or a novel (NUVISION™) 3D-ICE one (54 patients). Primary endpoint was a composite of procedural success and LAA sealing at follow-up TEE. Secondary endpoint was a composite of periprocedural device recapture/resizing plus presence of leaks ≥ 3 mm at follow-up TEE. 3D-ICE measurements of maximum landing zone correlated highly with pre-procedural TEE reference values [Pearson's: 0.94; P < 0.001; bias: -0.06 (-2.39, 2.27)]. The agreement between 3D-ICE-based device selection and final device size was 96.3% vs. 79.1% with 2D-ICE (P = 0.005). The incidence of the primary endpoint was 98.1% with 3D-ICE and 97.3% with 2D-ICE (P = 0.99). 2D-ICE patients had a trend towards a higher incidence of periprocedural device recapture/redeployment (31.5% vs. 44.5%; P = 0.09). The secondary endpoint occurred in 31.5% of 3D-ICE patients vs. 45.9% of 2D-ICE ones (P = 0.065)., Conclusion: Intracardiac echocardiography-guided LAAO showed a very high success, with no major adverse events. A very high level of agreement for LAA sizing was found between pre-procedural TEE and periprocedural 3D-ICE. 3D-ICE performed significantly better than 2D-ICE for FLX size selection and may provide better guidance during device deployment., Competing Interests: Conflict of interest: G.-B.C. received compensation from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical. C.d.A. received research grants on behalf of the centre from Biotronik, Medtronic, Abbott, LivaNova, Boston Scientific, AtriCure, Philips, and Acutus. D.J.B. is a consultant for Biosense Webster and Stereotaxis. L.D.B. is a consultant for Biosense Webster, Boston Scientific, Stereotaxis, and St. Jude Medical. A.N. received speaker honoraria from Boston Scientfic, Biosense Webster, St. Jude Medical, Biotronik, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.